Evotec is advancing drug discovery by targeting RNA splicing, a key regulatory step in gene expression.

A recent poster, by Mélanie Carquin, Project Leader in the HTP Biology & Screening Group at Evotec, presents:

• leverage of Evotec’s cutting edge high-throughput RT-qPCR platform to accelerate the identification and development of RNA splicing modulators
• use of advanced data analysis to identify, characterize and filter the most promising molecules for follow-up screening
• hit confirmation techniques at the protein level to ensure biological relevance

This innovative screening approach offers a powerful solution for developing therapeutics against previously "undruggable" targets.